PT  - JOURNAL ARTICLE
ED  - ,
TI  - ▼ Safinamide for Parkinson’s disease
AID  - 10.1136/dtb.2018.5.0623
DP  - 2018 May 01
TA  - Drug and Therapeutics Bulletin
PG  - 54--57
VI  - 56
IP  - 5
4099  - http://dtb.bmj.com/content/56/5/54.short
4100  - http://dtb.bmj.com/content/56/5/54.full
SO  - Drug Ther Bull2018 May 01; 56
AB  - ▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.